Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 12/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 12/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879657 | 0.87 | CFD (0.48) | CFD | |
| SCHEMBL21455344 | 0.81 | CFD (0.47) | CFDKDM4C | |
| SCHEMBL25879654 | 0.78 | CFD (0.72) | CFD | |
| SCHEMBL21455335 | 0.74 | PPID (0.45) | CFD | |
| SCHEMBL21455332 | 0.70 | CFD (1.00) | CFD | |
| SCHEMBL31215931 | 0.69 | BCL2 (0.61) | BCL2PTGS2 | |
| SCHEMBL212070 | 0.68 | KDM4E (0.42) | CSNK2A2CSNK2BKDM4C | |
| SCHEMBL10985563 | 0.67 | KDM4E (0.48) | DHODH | |
| SCHEMBL15610422 | 0.67 | KDM4E (0.51) | CSNK2A2CSNK2BKDM4CFGFR1 | |
| SCHEMBL24200064 | 0.66 | FGFR1 (0.44) | BCL2PTGS2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885BCL2 1175/4885CSNK2A2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.